{
    "clinical_study": {
        "@rank": "153140", 
        "arm_group": {
            "arm_group_label": "SERI\u00ae Surgical Scaffold", 
            "arm_group_type": "Experimental", 
            "description": "Subjects implanted with SERI\u00ae Surgical Scaffold for soft-tissue support during direct-to-implant breast reconstruction"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to prospectively observe clinical and economic outcomes with\n      the use of SERI\u00ae in direct-to-implant breast reconstruction."
        }, 
        "brief_title": "Clinical and Economic Outcomes With the Use of SERI\u00ae Surgical Scaffold in Direct-to-implant Breast Reconstruction", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Reconstruction", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be willing to undergo immediate breast reconstruction following a skin-sparing or\n             nipple sparing mastectomy with healthy, sufficiently thick, well-vascularized skin\n             flaps, and the implantation of SERI\u00ae Surgical Scaffold and breast implant\n\n          -  Be female, between 18 and 65 years of age at the time of enrollment\n\n        Exclusion Criteria:\n\n          -  Have undergone prior radiation treatment on the study breast(s) and/or is\n             preoperatively evaluated to require radiation treatment to the study breast(s) during\n             the course of the study\n\n          -  Have undergone a mastectomy in the study breast(s) with either a wise pattern,\n             vertical, circumvertical or peri-areolar incision of greater than 30% circumference\n             and not extending across the medial half of the nipple areolar complex (NAC)\n\n          -  Have undergone a skin reducing mastectomy\n\n          -  Have 3rd degree ptosis (as classified by the modified Regnault ptosis scale)\n\n          -  Have a BMI that is <17 or \u2265 30\n\n          -  Receive an implant size more than 100% of the excised breast weight\n\n          -  Predicted implant weight more than 500 grams\n\n          -  Have mastectomy weight greater than 600 grams\n\n          -  Have smoked within the last 2 years prior to surgery\n\n          -  Have any concurrent procedure on the study breast(s), except for lymph node sampling\n             or resection\n\n          -  Have mastectomy flaps that are deemed by the physician intra-operatively to be too\n             thin or have significant ischemia. This would be assessed by the operating surgeon\n             with a sizer or the definitive implant in place as having a capillary refill > 2\n             seconds, non-bleeding edges and mastectomy flap pallor. These subjects will be exited\n             from the study as screen failures and standard of care will be followed\n\n          -  Have collagen-vascular, connective tissue, or bleeding disorders\n\n          -  Have any disease clinically known to impact wound healing ability, including\n             uncontrolled diabetes with a documented HbA1c of \u2265 7.0mg/ml within 6 weeks prior to\n             study entry\n\n          -  Have a positive nasal swab for either Methicillin-Sensitive Staphylococcus Aureus\n             (MSSA) or Methicillin-Resistant Staphylococcus Aureus (MRSA)\n\n          -  Have a known allergy to silk\n\n          -  Have uncontrolled hypertension\n\n          -  Have documented autoimmune disease or an immune deficiency\n\n          -  Have undergone neo adjuvant chemotherapy\n\n          -  Taking immunosuppressive drugs with the exception of chemotherapeutics\n\n          -  Require the use of any additional medical device for soft tissue support of the\n             contralateral breast, except in bilateral breast reconstructions, where the use of\n             SERI\u00ae Surgical Scaffold is allowed\n\n          -  Planned tissue flap in addition to prosthetic implant\n\n          -  Have undergone previous surgery (mastectomy, breast augmentation, mastopexy) on the\n             study breast(s) with the exception of open breast biopsy, cyst removal and breast\n             conserving lumpectomy\n\n          -  Have had a prior soft tissue support device implanted in the study breast\n\n          -  Currently have an alcohol/substance abuse problem or have had a relapse within 1 year\n             prior to screening visit\n\n          -  Have documented history of mental disease/disorder exclusive of depression /anxiety\n\n          -  Have concomitant unrelated condition of breast/chest wall/skin (e.g. significant\n             chest wall abnormalities including pectus excavatum or pectus carinatum)\n\n          -  Have an abscess or active infection at any location within one month prior to surgery\n\n          -  Have surgery that will involve the use of an investigational breast implant\n\n          -  Be pregnant, lactating, or if of childbearing potential, be unwilling to use\n             contraceptive methods and avoid pregnancy throughout the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033590", 
            "org_study_id": "SURE-005"
        }, 
        "intervention": {
            "arm_group_label": "SERI\u00ae Surgical Scaffold", 
            "description": "A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, transitory silk scaffold indicated for use in soft tissue support and repair", 
            "intervention_name": "Biodegradable (purified) surgical silk scaffold", 
            "intervention_type": "Device", 
            "other_name": "SERI\u00ae Surgical Scaffold"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Implant based", 
            "breast reconstruction", 
            "soft tissue support device"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multi-center Study to Observe Clinical and Economic Outcomes With the Use of SERI\u00ae Surgical Scaffold (SERI\u00ae) in Direct-to-implant Breast Reconstruction", 
        "overall_contact": {
            "email": "devicetrials@allergan.com", 
            "last_name": "Allergan Medical"
        }, 
        "overall_official": {
            "affiliation": "Allergan Medical", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "UK: specific REC not known yet (will be provided after submission is done) and local R&D committees", 
                "Italy: MoH (CA) notification will be done, but study will be reviewed by local EC Rome hospital"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence rate of implant loss (SERI\u00ae and breast implant)", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033590"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}